Researchers from the University of Washington (UW) School of Medicine claimed that a newly developed "nanoparticle" coronavirus vaccine can fight future mutated strains more effectively than other vaccines. They also explained that it can make your immune system ten times stronger than the immune responses seen in COVID-19 survivors.
According to Sci-Tech Daily's latest report, the scientists used UW Medicine's structure-based vaccine design to develop the new COVID-19 drug. It can display 60 copies of the SARS-CoV-2 Spike protein's receptor-binding domain in a highly immunogenic array.
The self-assembling protein nanoparticle can also provoke a strong memory cell response, helping the body remember the invading viral particles and produce antibodies faster.
The new COVID-19 vaccine produces more antibodies
What's great about this innovation is that it no longer needs freezer storage, as reported by the Daily Mail UK. This makes the drug easier to produce and transfer across the globe, just like other vaccines.
Aside from its storage ability, the vaccine can also produce more neutralizing antibodies.
"We hope that our nanoparticle platform may help fight this pandemic that is causing so much damage to our world," said Dr. Neil King, one of the UW School of Medicine's biochemistry assistant professor.
"The potency, stability, and manufacturability of this vaccine candidate differentiate it from many others under investigation," he added.
How it enhances immune response
Scientists explained that synthetic or natural nanoparticles can mimic structural features of viral diseases. They can do this since the viruses mostly have the same size as nanoparticles.
Because the new vaccine also has the same ability, allowing it to mold to the shape and size of virus receptors effortlessly. The nanoparticle COVID-19 vaccine can train the body to recognize the virus receptors.
Once the body cells are familiar with the viral particles, it can fight them by building more antibodies than usual. They can also prevent future infections before they even start.
The researchers first tested the innovation on mice and published the results in the journal Cell.
For more news updates about new COVID-19 vaccines, always keep your tabs open here at TechTimes.
Related Article : Antibodies Now 'Rogue,' Cells Attacking Body Instead of Virus Causing Long COVID-19
This article is owned by TechTimes.
Written by: Giuliano de Leon.
